Pfizer to acquire obesity-focused biopharma Metsera for up to $7.3 billion, expanding its pipeline of oral and injectable therapies.
U.S. existing home sales hit a 10-year low in August amid high prices, but improving mortgage rates and growing inventory are expected to boost market activity.
Pfizer to acquire obesity-focused biopharma Metsera for up to $7.3 billion, expanding its pipeline of oral and injectable therapies.
U.S. existing home sales hit a 10-year low in August amid high prices, but improving mortgage rates and growing inventory are expected to boost market activity.